Roger Green interviews physician, author, and entrepreneur Marcus Ranney about his experiences, the ability of data and digital health to empower health seekers, and the foundational vision that led him to form Human Edge and develop the Mito app.
Louise Campbell and Roger Green interview Arizona Liver Health Institute V.P. of Academic Affairs and Fatty Liver Program Director Naim Alkhouri and Global Liver Institute Founder and CEO Donna Cryer about their recent projects and accomplishments.
Scott Friedman discusses that background for the potential breakthrough work from Jon Epstein at the University of Pennsylvania on how combined mRNA/CAR-T therapy can regress fibrosis in mouse CVD models.
This Episode Is Sponsored By Madrigal Pharmaceuticals. What Insights About NASH and NAFLD Emerged From the Chronic Liver Disease Foundation’s 2nd Annual Liver Connect and NASH Connect?
What is the impact of the NICE Draft Guidance on Community and Primary Care NAFLD Screening with FibroScan not analyzing the long-term impact of a decision not to compensate on health care in the UK?
Does the NICE Draft Guidance and methodology reveal a bad fit between the NICE mode of analysis and wellness-oriented solutions like early NAFLD screening?
What can we learn about prospects for community screening for NAFLD from the NICE draft guidance on this issue?
Jeff Lazarus And Jörn Schattenberg of the Innovations in NAFLD Care 2022 Series join the Surfers to consider innovative elements for a program like this along with the outcomes they would like these programs to produce.
Jeff Lazarus And Jörn Schattenberg of the Innovations in NAFLD Care 2022 Series join the Surfers to discuss the structural healthcare issues that are shaping the Fatty Liver pandemic and why education is such an important part of the solution.
Co-chairs Jeff Lazarus and Jörn Schattenberg of the Innovations in NAFLD Care 2022 Series join the Surfers to review the initiative’s key elements and patient awareness goals.
